HC Wainwright reissued their buy rating on shares of TuHURA Biosciences (NASDAQ:HURA – Free Report) in a report published on Tuesday,Benzinga reports. HC Wainwright currently has a $10.00 price target on the stock.
A number of other research analysts also recently issued reports on the company. Citizens Jmp reaffirmed a “market outperform” rating and set a $9.00 price target on shares of TuHURA Biosciences in a report on Tuesday, August 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Thursday, October 15th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, TuHURA Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $9.00.
View Our Latest Report on TuHURA Biosciences
TuHURA Biosciences Price Performance
Shares of NASDAQ HURA opened at $2.06 on Tuesday. TuHURA Biosciences has a twelve month low of $0.41 and a twelve month high of $3.43. The firm has a market cap of $131.28 million, a P/E ratio of -3.81 and a beta of -0.21. The company has a 50 day moving average of $2.03 and a 200 day moving average of $1.95. The company has a quick ratio of 0.18, a current ratio of 0.18 and a debt-to-equity ratio of 0.20.
TuHURA Biosciences (NASDAQ:HURA – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. As a group, research analysts expect that TuHURA Biosciences will post -0.57 EPS for the current fiscal year.
Institutional Investors Weigh In On TuHURA Biosciences
Hedge funds have recently added to or reduced their stakes in the stock. Merck & Co. Inc. boosted its stake in shares of TuHURA Biosciences by 39.4% in the 1st quarter. Merck & Co. Inc. now owns 19,445 shares of the company’s stock worth $35,000 after buying an additional 5,495 shares during the last quarter. HighTower Advisors LLC grew its holdings in shares of TuHURA Biosciences by 42.5% in the second quarter. HighTower Advisors LLC now owns 30,151 shares of the company’s stock worth $71,000 after acquiring an additional 8,999 shares during the period. PFG Investments LLC increased its position in TuHURA Biosciences by 39.4% during the first quarter. PFG Investments LLC now owns 32,630 shares of the company’s stock valued at $58,000 after acquiring an additional 9,219 shares during the last quarter. Two Sigma Securities LLC purchased a new stake in TuHURA Biosciences during the second quarter valued at $33,000. Finally, Bank of America Corp DE lifted its holdings in TuHURA Biosciences by 24.0% in the first quarter. Bank of America Corp DE now owns 78,142 shares of the company’s stock valued at $140,000 after acquiring an additional 15,135 shares during the period. 0.62% of the stock is currently owned by hedge funds and other institutional investors.
TuHURA Biosciences Company Profile
TuHURA Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is directed toward treatments intended to address mechanisms that enable tumors to evade the immune system and resist existing cancer therapies.
TuHURA’s lead product candidate, IFx-2, is an investigational cancer immunotherapy designed for intratumoral administration. The program is intended to stimulate a broader anti-tumor immune response and potentially improve the effectiveness of immune checkpoint inhibitors and other established treatments.
Featured Articles
- Five stocks we like better than TuHURA Biosciences
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
